CN Patent

CN112625028B — 用于抑制shp2活性的化合物和组合物

Assigned to Novartis AG · Expires 2024-10-29 · 2y expired

What this patent protects

本发明涉及式I化合物。所述化合物是Scr Homolgy‑2磷酸酶(SHP2)的抑制剂，因而可用于治疗努南综合征、豹斑综合征和癌症。

USPTO Abstract

本发明涉及式I化合物。所述化合物是Scr Homolgy‑2磷酸酶(SHP2)的抑制剂，因而可用于治疗努南综合征、豹斑综合征和癌症。

Drugs covered by this patent

neratinib-maleate (NERATINIB MALEATE)

Patent Metadata

Patent number: CN112625028B
Jurisdiction: CN
Classification: —
Expires: 2024-10-29
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.